Hypothesis

Aging alters gut microbiota composition, increasing production of phenylacetic acid (PAA) which chronically activates enterochromaffin (EC) cells via aryl hydrocarbon receptor pathways, driving mitochondrial ROS accumulation, senescence‑associated secretory phenotype (SASP) and a progressive loss of tryptophan hydroxylase 1 (TPH1) activity. Concurrently, age‑dependent downregulation of FFAR2 receptors reduces responsiveness to beneficial SCFAs, further diminishing 5‑HT release. Together, these mechanisms impair local 5‑HT signaling and contribute to age‑related gastrointestinal motility disorders.

Mechanistic Basis

• Microbiota shift: Longitudinal studies show enrichment of PAA‑producing Clostridia species in older humans, raising luminal PAA levels (cite: [https://pmc.ncbi.nlm.nih.gov/articles/PMC9630942/]).
• PAA‑induced senescence: PAA triggers endothelial cell senescence through mitochondrial H₂O₂ and p16^INK4a^ upregulation (cite: [https://doi.org/10.1101/2023.11.17.567594]). EC cells express similar oxidative stress sensors and aryl hydrocarbon receptors, making them susceptible to the same pathway.
• EC‑specific impact: Senescent EC cells exhibit SASP factors (IL‑6, TGF‑β) that inhibit TPH1 transcription via SMAD‑dependent repression, directly cutting 5‑HT synthesis.
• FFAR2 desensitization: Aging reduces FFAR2 mRNA in EC cells (cite: [https://pmc.ncbi.nlm.nih.gov/articles/PMC12547937/]), weakening butyrate‑mediated cAMP signaling that normally potentiates vesicle exocytosis.
• Local 5‑HT deficit: Because gut‑derived 5‑HT acts chiefly on epithelial 5‑HTR4 receptors (cite: [https://pmc.ncbi.nlm.nih.gov/articles/PMC9630942/]), diminished release translates into slower propulsive contractions and constipation‑like phenotypes.

Testable Predictions

1. Metabolite correlation: In human colon biopsies across decades, PAA concentration will positively correlate with senescence markers (p21, SA‑β‑gal) and negatively with TPH1 protein levels in EC cells (immunofluorescence).
2. Receptor expression: Quantitative PCR will show a significant age‑related decline in FFAR2 (and OR51E1) transcripts isolated from laser‑captured EC cells, while aryl hydrocarbon receptor (AHR) expression remains stable or increases.
3. Functional rescue: Treating aged mouse colonic organoids with a PAA scavenger (e.g., benzoic acid) or an AHR antagonist will reduce ROS, lower SASP secretion, and restore 5‑HT release measured by ELISA.
4. Microbiota transfer: Transplanting feces from old donors into germ‑free young mice will elevate colonic PAA, increase EC cell senescence markers, and slow gastrointestinal transit compared with transplants from young donors.
5. FFAR2 agonist efficacy: Chronic administration of a selective FFAR2 agonist (e.g., 4‑CMTB) in aged animals will partially rescue 5‑HT output and improve motility, even without altering PAA levels.

Falsifiability

If any of the following observations hold, the hypothesis is weakened:

• No age‑dependent rise in colonic PAA or its producers.
• EC cell senescence markers do not increase with age despite elevated PAA.
• TPH1 activity remains unchanged in senescent EC cells isolated from aged tissue.
• FFAR2 expression shows no decline with age, and FFAR2 agonism fails to enhance 5‑HT release.
• Microbiota transfers from old to young recipients do not recapitulate EC cell senescence or motility deficits.

By linking microbiota metabolite flux, receptor signaling changes, and cellular senescence, this hypothesis provides a concrete, experimentally tractable framework to explain how EC cell dysfunction may drive age‑related gut motility decline.